C4 therapeutics presents preclinical data on cft7455, a novel ikzf1/3 degrader for the treatment of hematologic malignancies, at the aacr annual meeting 2021

– cft7455 demonstrated high cereblon binding affinity and rapid, deep ikzf1/3 degradation enabling activity across a panel of multiple myeloma cell lines including imid-resistant models –

CCCC Ratings Summary

CCCC Quant Ranking